In triple-negative breast cancer (TNBC), GPNMB overexpression correlates with poor prognosis and demonstrates therapeutic vulnerability, as evidenced by CDX-011 (anti-GPNMB ADC) achieving 40% objective response rates. The gene discussed is GPNMB; the disease is triple-negative breast carcinoma.